HUTCHMED (CHINA) LIMIT

18,43

27-ноября-24 15:45:00

15 мин. задержка

Акции

+1,05

+6,04%

Сегодняшний диапазон

18,29 - 18,57

ISIN

N/A

Источник

NASDAQ

HUTCHMED Included in FTSE Russell Indexes

19 дек 2021 18:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting

13 дек 2021 23:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

10 дек 2021 04:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

05 дек 2021 18:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China

02 дек 2021 23:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

23 ноя 2021 18:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

07 ноя 2021 18:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma

31 окт 2021 23:15:00 Источник Nasdaq GlobeNewswire
HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

27 окт 2021 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

28 сен 2021 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture

28 сен 2021 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China

20 сен 2021 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

19 сен 2021 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

13 сен 2021 01:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

08 сен 2021 05:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference

07 сен 2021 03:30:00 Источник Nasdaq GlobeNewswire
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

06 сен 2021 01:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

25 авг 2021 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED Selected as Constituent of Certain Hang Seng Indexes

22 авг 2021 19:00:00 Источник Nasdaq GlobeNewswire
HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

08 авг 2021 19:00:00 Источник Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.